Trials / Terminated
TerminatedNCT04579666
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Subjects With Amyotrophic Lateral Sclerosis (ALS)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 249 (actual)
- Sponsor
- Apellis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a 24-month, Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pegcetacoplan in subjects with amyotrophic lateral sclerosis (ALS)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegcetacoplan (APL-2) | Complement (C3) Inhibitor |
| OTHER | Placebo | Sterile solution of equal volume to active arm |
Timeline
- Start date
- 2020-09-30
- Primary completion
- 2023-03-31
- Completion
- 2023-07-13
- First posted
- 2020-10-08
- Last updated
- 2025-04-24
- Results posted
- 2025-04-24
Locations
60 sites across 14 countries: United States, Australia, Belgium, Czechia, France, Germany, Ireland, Italy, Japan, Netherlands, Poland, Spain, Ukraine, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04579666. Inclusion in this directory is not an endorsement.